What question did this study set out to answer?

February 2, 2026TrialsOpen Access

A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)

View Full Paper

Ask AI

Bookmark

The study aims to evaluate the effectiveness of an optimized dose of rifampicin and moxifloxacin for treating drug-susceptible pulmonary tuberculosis.
Conducting an open-label, randomized phase III trial.
Participants will receive optimized doses of rifampicin and moxifloxacin.
The trial is registered under ClinicalTrials.gov NCT05575518.
Effectiveness of optimized drug doses on treatment outcomes for tuberculosis is expected to be assessed.
Detailed quantitative results will be reported upon study completion.

We only have this paper's title and publication details.

Open-label randomized phase III trial evaluates treatments for drug-susceptible tuberculosis, indicating potential improvements in therapy.

ClinicalTrials.gov NCT05575518. Registered on 10th October 2022.

No takes yet. Share an insight, caveat, or question.

Mlyuka et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Open-label randomized phase III trial evaluates treatments for drug-susceptible tuberculosis, indicating potential improvements in therapy.

ClinicalTrials.gov NCT05575518. Registered on 10th October 2022.